Chemical Compound

Semaxanib

CAS Registry Number 204005-46-9
Back to search Request a Quote
Semaxanib chemical structure
Primary Record

Semaxanib

In stock
9,271 g
Purity
99.0 %
CAS
204005-46-9

Compound Identifiers & Properties

CAS
204005-46-9
PubChem CID
5329098
SMILES
CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C
Canonical SMILES
Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1

Names & Synonyms

  • Semaxanib
  • Semaxinib
  • Semoxind
  • SU5416
  • SU 5416
  • Romiplostim
  • Semaxnib
  • Semaxanib (SU5416)
  • Z-Semaxanib
  • Romiplate
  • 204005-46-9
  • 194413-58-6
  • InSolution&trade
  • Semaxanib [INN]
  • test2
  • (Z)-Semaxanib
  • SU-5416
  • Semaxanib (USAN/INN)
  • Semaxanib [USAN:INN]
  • Sugen 5416
  • TSU 16
  • TSU-16
  • 2x2m
  • Semaxanib; SU5416
  • SEMAXANIB [USAN]
  • methylene]-2H-indol-2-one
  • Semaxanib (u-5416)
  • UNII-71IA9S35AJ
  • D01PZD
  • D04ADG
  • D0QY0V
  • Semaxanib (SU5416)?
  • SEMAXANIB [MART.]
  • VEGFR2 Kinase Inhibitor III
  • SEMAXANIB [WHO-DD]
  • 71IA9S35AJ
  • CHEMBL276711
  • Lopac0_001110
  • SCHEMBL19571
  • C15H14N2O
  • MLS001074896
  • MLS001332519
  • MLS001332520
  • NSC-696819
  • VEGF Receptor 2 Kinase Inhibitor III
  • MFCD09763655
  • WUWDLXZGHZSWQZ-WQLSENKSSA-N
  • AC1NS627
  • BDBM4810
  • GTPL5056
  • orb1305395
  • QCR-86
  • SCHEMBL5559276
  • DTXCID9021132
  • DTXSID1041132
  • SCHEMBL29351025
  • CHEBI:91083
  • cid_5329098
  • (Z)-SU 5416
  • AOB6828
  • SIBNPBQTUXWRMZ-ZSOIEALJSA-N
  • BDBM497339
  • DTXSID801025708
  • HMS2234L12
  • HMS3229O13
  • HMS3263M22
  • HMS3268J13
  • HMS3413H10
  • HMS3648O12
  • HMS3677H10
  • NSC 696819
  • (Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one
  • AMY10847
  • BCP06068
  • CS-AD-00525
  • EX-A2158
  • Tox21 111271
  • Tox21_111271
  • Tox21_501110
  • 2033AH
  • 2712AH
  • C15-H14-N2-O
  • HSCI1_000303
  • MFCD01940922
  • NCGC00094381-03
  • NSC696819
  • s2845
  • SU5146
  • ZINC12410091
  • SU005416
  • AKOS015994557
  • AKOS040744647
  • Tox21_111271_1
  • AN-3643
  • CCG-205186
  • CID5329098
  • CS-1225
  • DB06436
  • EBC-222025
  • ES-0010
  • FD65177
  • LP01110
  • SDCCGSBI-0051079.P003
  • SDCCGSBI-0051079.P007
  • CID:5329098
  • US11001595, Compound SU5416
  • (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one
  • NCGC00094381-01
  • NCGC00094381-02
  • NCGC00094381-04
  • NCGC00094381-05
  • NCGC00094381-06
  • NCGC00094381-19
  • NCGC00261795-01
  • AC-35250
  • BC600544
  • DA-67820
  • HY-10374
  • LS-83886
  • QC-11357
  • SC-96714
  • SMR000568416
  • 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-2-indolinon
  • S 8442
  • SID:135653357
  • AB0094985
  • LS-193151
  • RT-016226
  • 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one
  • A3847
  • CAS-204005-46-9
  • EU-0101110
  • FT-0688745
  • FT-0771090
  • NS00070556
  • SW219791-1
  • 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)
  • J1.051.859H
  • J2.299.233C
  • 3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one
  • A12437
  • D05819
  • N11132
  • W-5403
  • 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone
  • 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one
  • 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one
  • A899499
  • C549241
  • InSolution™ VEGF Receptor 2 Kinase Inhibitor III
  • SR-01000076044
  • (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]indolin-2-one
  • 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
  • 2H-Indol-2-one,5-dimethyl-2-pyrrolyl)methylene]-
  • 3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole
  • Q7449140
  • SR-01000076044-2
  • SR-01000076044-8
  • BRD-K63504947-001-05-5
  • BRD-K63504947-001-14-7
  • BRD-K63504947-001-15-4
  • BRD-K63504947-001-16-2
  • BRD-K63504947-001-17-0
  • 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one
  • 3-((2,4-dimethylpyrrol-5-yl)methylidenyl)-2-indolinone
  • 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone
  • H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-
  • (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
  • (3Z)-3-[(3,5-DIMETHYL-1H-PYRROL-2-YL)METHYLIDENE]-2,3-DIHYDRO-1H-INDOL-2-ONE
  • 3-(2,4-Dimethyl-1H-pyrrole-5-ylmethylene)-2-indolinone
  • 3-(3,5-Dimethyl-1H-pyrrole-2-ylmethylene)indoline-2-one
  • 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one
  • Semaxanib, Semoxind, TSU-16, NSC-696819, SU-5416
  • 3-[(3,5-Dimethyl-1H-pyrrole-2-yl)methylene]indoline-2-one
  • 3-[(3,5-Dimethyl-2H-pyrrol-2-ylidene)methyl]-1H-indol-2-ol
  • (3Z)-3-[(3,5-Dimethyl-1H-pyrrole-2-yl)methylene]indoline-2-one
  • (E)-3-((3,5-Dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one
  • 3-[(3,5-Dimethyl-1H-pyrrole-2-yl)methylene]-1H-indole-2(3H)-one
  • (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-oneEE
  • 186610-95-7
  • 267639-76-9
  • 3-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- 2H-indol-2-one
  • 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-2h-indol-2-one
  • 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
  • 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-2,3-dihydro-1H-indol-2-one
  • 3-[(Z)-(3,5-Dimethyl-1H-pyrrole-2-yl)methylene]-1H-indole-2(3H)-one
  • (3E)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-2,3-dihydro-1H-indol-2-one
  • (3Z)-3-((3,5-DIMETHYL-1H-PYRROL-2-YL)METHYLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONE
  • (3Z)-3-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one
  • 2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (3Z)-
  • 2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (Z)-
  • 2H-Indol-2-one, 3-(3,5-dimethyl-1H-pyrrol-2-yl)methylene)- 1,3-dihydro-, (Z)-
  • 2H-INDOL-2-ONE, 3-(3,5-DIMETHYL-1H-PYRROL-2-YL)METHYLENE)- 1,3-DIHYDRO-,(Z)-
  • 3-[(Z)-(3,5-Dimethyl-1H-pyrrole-2-yl)methylene]-2,3-dihydro-1H-indole-2-one
  • 3-[1-(3,5-dimethyl-1h-pyrrol-2-yl)-meth-(z)-ylidene]-2-oxo-2,3-dihydro-indole
  • 194413-57-5